Titre
validation prospective de biomarqueurs dans le sarcome d'ewing pour une médicine translationnelle personnalisée
Titre en anglais
prospective validation of biomarkers in ewing sarcoma for personalised translational medecineNom de l'appel à projet (acronyme)
TRANSCAN12Année de financement
2012Durée (en mois)
36Porteur principal
DELATTRE Olivier , Institut Curie26, rue d'Ulm
75005 PARIS
Équipes associées
DIRKSEN Uta / University Children's Hospital Münster
Présentation
Résumé
ce projet associe trois group leader au niveau européen sur les essais cliniques concernant le sarcome d'ewing: le groupe euroewing, le groupe "sarcomes" italien et le groupe "sarcomes" espagnol. ces différents groupes souhaitent combiner leurs efforts pour identifier les biomarqueurs indispensables pour mieux préciser le risque évolutif de la maladie et établir les stratifications thérapeutiques,
Résumé en anglais
provabes prospective validation of biomarkers in ewing sarcoma for personalized translational medicine the majority of ewing sartcoma patients are treated within clinical trials under the auspices of the clinical trial groups cooperating in this consortium. owing to multimodal treatment approaches, including high-intensity chemotherapy regimens, surgery and radiotherapy, 2, 3 of the patients with localized disease achieve sustained remission- ~30 % relapse. it is of concern that, in contrast to the general trend in young cancer patients, the outcome in es failed to improve markedly in the last two decades. moreover, long-term survivors are prone to develop severe late sequelae of high-intensity treatments. while clinical prognostic markers such as primary dissemination, tumour site, size, patient`s age and histological response to chemotherapy are established and used for therapeutic stratification, little is known about biological factors that determine the risk of relapse or progression and thus might help to differentiate patients at risk from those eligible for less intense treatment. prospectively validated biomarkers are thus needed to provide personalised risk-adapted therapeutic approaches. our group has recently published promising biomarkers. the aim of provabes is the careful validation of chr 1q gain, chr 16 alteration, expression of hsa-mir34a, mgst1, lgals3bp and steap1 in a prospective joint investigation. these prognostic s tudies will complement on-going circulating biomarkers studies and proposed exploratory studies on activity of promising candidates and lead to a common dataset of precisely described es.
Carte
2121
validation prospective de biomarqueurs dans le sarcome d'ewing pour une médicine translationnelle personnalisée
26, rue d'Ulm
75005 PARIS